Fig. 2 | Scientific Reports

Fig. 2

From: Complete preclinical evaluation of the novel antibody mimetic Nanofitin-IRDye800CW for diverse non-invasive diagnostic applications in the management of HER-2 positive tumors

Fig. 2

Nanofitin competition analysis with Trastuzumab and Pertuzumab antibodies. (a-d), NF-Cys competition analysis with Trastuzumab and Pertuzumab for the binding site by competitive ELISA assay. (a, b), Duplicate plates were incubated with Streptavidin-HRP for antibody signal detection or with anti-RSGH Tag-HRP for Nanofitin signal detection. n = 2, mean ± SD. (c, d), Binding of Trastuzumab or Pertuzumab in presence or absence of NF-Cys. n = 2, mean ± SD. (e, f), NF-800 binding on OE-19 cells in presence of variable excess of Trastuzumab-Alexa-488. n = 2, mean ± SD. (e), Acquisition with flow cytometry setting on IRDye800CW wavelengths; (f), acquisition with flow cytometry setting on Alexa-488 wavelengths.

Back to article page